Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A compound of Formula I



I

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

Ar is phenyl or naphthyl;

A is selected from: $-CO_2H$, 1*H*-tetrazol-5-yl, $-PO_3H_2$, $-PO_2H_2$, $-SO_3H$, and $-PO(R^5)OH$, wherein R^5 is selected from the group consisting of: C_{1-4}alkyl , hydroxyC_{1-4}alkyl, phenyl, $-C(O)-C_{1-3}$alkoxy and -CH(OH)-phenyl, said phenyl and phenyl portion of -CH(OH)-phenyl optionally substituted with 1-3 substituents independently selected from the group consisting of: hydroxy, halo, $-CO_2H$, C_{1-4}alkyl, $-S(O)_kC_{1-3}$alkyl, wherein k is 0, 1 or 2, C_{1-3}alkoxy, C_{3-6} cycloalkoxy, aryl and aralkoxy, the alkyl portions of said C_{1-4}alkyl, $-S(O)_kC_{1-3}$alkyl, C_{1-3}alkoxy and C_{3-6} cycloalkoxy optionally substituted with 1-3 halo groups;

n is 2, 3 or 4;

each R^1 and R^2 is each independently selected from the group consisting of: hydrogen, halo, hydroxy, $-CO_2H$, C_{1-6}alkyl and phenyl, said C_{1-6}alkyl and phenyl optionally substituted with 1-3 halo groups;

R^3 is selected from the group consisting of: hydrogen and C_{1-4}alkyl, optionally substituted with 1-3 hydroxy or halo groups;

each R^4 is independently selected from the group consisting of: hydroxy, halo, $-CO_2H$, C_{1-4}alkyl, $-S(O)_kC_{1-3}$alkyl, wherein k is 0, 1 or 2, C_{1-3}alkoxy, C_{3-6} cycloalkoxy, aryl and aralkoxy, the alkyl portions of said C_{1-4}alkyl, $-S(O)_kC_{1-3}$alkyl, C_{1-3}alkoxy and C_{3-6} cycloalkoxy optionally substituted with 1-3 halo groups;

C is selected from the group consisting of:

(1) C_{1-8}alkyl, C_{1-8}alkoxy, $-(C=O)-C_{1-6}$alkyl or $-CHOH-C_{1-6}$alkyl, said C_{1-8}alkyl, C_{1-8}alkoxy, $-(C=O)-C_{1-6}$alkyl and $-CHOH-C_{1-6}$alkyl optionally substituted with phenyl, and

(2) phenyl or HET, each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl, C_{1-4}alkyl and C_{1-4}alkoxy, said C_{1-4}alkyl and C_{1-4}alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo and C_{1-4}alkyl, optionally substituted with 1-3 halo groups,

or **C** is not present;

when **C** is not present then **B** is selected from the group consisting of: phenyl, C_{5-16}alkyl, C_{5-16}alkenyl, C_{5-16}alkynyl, $-CHOH-C_{4-15}$alkyl, $-CHOH-C_{4-15}$alkenyl, $-CHOH-C_{4-15}$alkynyl, C_{4-15}alkoxy, $-O-C_{4-15}$alkenyl, $-O-C_{4-15}$alkynyl, C_{4-15}alkylthio, $-S-C_{4-15}$alkenyl, $-S-C_{4-15}$alkynyl, $-CH_2-C_{3-14}$alkoxy, $-CH_2-O-C_{3-14}$alkenyl, $-CH_2-O-C_{3-14}$alkynyl, $-(C=O)-C_{4-15}$alkyl, $-(C=O)-C_{4-15}$alkenyl, $-(C=O)-C_{4-15}$alkynyl, $-(C=O)-O-C_{3-14}$alkyl, $-(C=O)-O-C_{3-14}$alkenyl, $-(C=O)-O-C_{3-14}$alkynyl, $-(C=O)-N(R^6)(R^7)-C_{3-14}$alkyl, $-(C=O)-N(R^6)(R^7)-C_{3-14}$alkenyl, $-(C=O)-N(R^6)(R^7)-C_{3-14}$alkynyl, $-N(R^6)(R^7)-(C=O)-C_{3-14}$alkyl, $-N(R^6)(R^7)-(C=O)-C_{3-14}$alkenyl and $-N(R^6)(R^7)-(C=O)-C_{3-14}$alkynyl,

when **C** is phenyl or HET then **B** is selected from the group consisting of: C_{1-6}alkyl, C_{1-5}alkoxy, $-(C=O)-C_{1-5}$alkyl, $-(C=O)-O-C_{1-4}$alkyl, $-(C=O)-N(R^6)(R^7)-C_{1-4}$alkyl,



, phenyl and HET, and

when **C** is C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl or –CHOH-C_{1-6}alkyl then **B** is phenyl; and

R^6 and R^7 are independently selected from the group consisting of: hydrogen, C_{1-9}alkyl and -$(CH_2)_p$-phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of: C_{1-3}alkyl and C_{1-3}alkoxy, each optionally substituted with 1-3 halo groups.

2. (original) The compound according to Claim 1 wherein HET is selected from the group consisting of:



3. (original) The compound according to Claim 1 wherein n is 2.

4. (original) The compound according to Claim 1 wherein n is 3.

5. (original) The compound according to Claim 3 wherein each R^1 and R^2 is independently selected from the group consisting of: hydrogen, -CO_2H, hydroxy, halo, C_{1-3}alkyl and phenyl.

6. (original) The compound according to Claim 1 wherein **A** is PO_3H_2.

7. (original) The compound according to Claim 1 wherein **A** is –CO_2H.

8. (original) The compound according to Claim 1 wherein **A** is $PO(R^5)OH$, wherein R^5 is selected from the group consisting of: C_{1-4}alkyl, hydroxyC_{1-4}alkyl, C(O)-C_{1-2}alkoxy and benzyl, wherein both the methyl and phenyl portions of said benzyl are optionally substituted with 1-3 halo or hydroxy groups.

9. (original) The compound according to Claim 1 wherein **A** is PO_2H_2.

10. (original) The compound according to Claim 1 wherein **A** is 1*H*-tetrazol-5-yl.

11. (original) The compound according to Claim 1 wherein R^3 is hydrogen or methyl.

12. (original) The compound according to Claim 1 wherein each R^4 is independently selected from the group consisting of: halo, hydroxy, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, phenyl, benzyloxy and cyclopropyloxy.

13. (orignal) The compound according to Claim 1 wherein **B** is C_{8-10}alkyl and **C** is not present.

14. (original) The compound according to Claim 1 wherein **B** is C_{4-11}alkoxy and **C** is not present.

15. (original) The compound of according to Claim 1 wherein **B** is phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, C_{1-4}alkyl and C_{1-4}alkoxy, and **C** is selected from the group consisting of: hydrogen, phenyl, C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl and –CHOH-C_{1-6}alkyl, said C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl and –CHOH-C_{1-6}alkyl optionally substituted with phenyl.

16. (original) The compound according to Claim 1 wherein **B** is selected from the group consisting of: -CHOH-C_{6-10}alkyl, C_{6-10}alkylthio, -CH_2-C_{5-9}alkoxy, -(C=O)-C_{6-10}alkyl, -(C=O)-O-C_{5-9}alkyl, -(C=O)-N(R^6)(R^7)-C_{5-9}alkyl, -N(R^6)(R^7)-(C=O)-C_{5-9}alkyl, and **C** is not present.

17. (original) The compound according to Claim 1 wherein **B** is C_{1-6}alkyl or C_{1-5}alkoxy and **C** is phenyl.

18. (original) The compound according to Claim 1 wherein **B-C** is



or



19. (original) The compound according to Claim 1 wherein Ar is phenyl and the group **–B-C** is attached to the phenyl ring at the 3- or 4-position.

20. (original) A compound of Formula II



II

or a pharmaceutically acceptable salt or hydrate thereof, wherein

the group **–B-C** is attached to the phenyl ring at the 3- or 4-position;

n is 2, 3 or 4;

each R^1 and R^2 is independently selected from the group consisting of: hydrogen, -CO_2H, hydroxy, halo, C_{1-3}alkyl and phenyl, said C1-3alkyl and phenyl optionally substituted with 1-3 halo group;

A is selected from the group consisting of: 1*H*-tetrazol-5-yl, PO_2H_2, PO_3H_2, –CO_2H and $PO(R^5)OH$, wherein R^5 is selected from the group consisting of: C_{1-4}alkyl, hydroxyC_{1-4}alkyl, C(O)-C_{1-2}alkoxy and benzyl, wherein both the methyl and phenyl portions of said benzyl are optionally substituted with 1-3 halo or hydroxy groups;

R^3 is hydrogen or methyl;

each R^4 is independently selected from the group consisting of: halo, hydroxy, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylthio, phenyl, benzyloxy and cyclopropyloxy; and

B-C is selected from the group consisting of:

(1) **B** is C_{8-10}alkyl and **C** is not present.

(2) **B** is C_{4-11}alkoxy and **C** is not present.

(3) **B** is phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, C_{1-4}alkyl and C_{1-4}alkoxy, and **C** is selected from the group consisting of: hydrogen, phenyl, C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl and –CHOH-C_{1-6}alkyl, said C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl and –CHOH-C_{1-6}alkyl optionally substituted with phenyl;

(4) **B** is -CHOH-C_{6-10}alkyl, C_{6-10}alkylthio, -CH_2-C_{5-9}alkoxy, -(C=O)-C_{6-10}alkyl, -(C=O)-O-C_{5-9}alkyl, -(C=O)-N(R^6)(R^7)-C_{5-9}alkyl or -N(R^6)(R^7)-(C=O)-C_{5-9}alkyl, and **C** is not present.

(5) **B** is C_{1-6}alkyl or C_{1-5}alkoxy and **C** is phenyl.

(6) **B-C** is



or



21. (original) A compound selected from the group consisting of:






Abs
OH
OH
N
O
CH3
F
F
HO—P=O
Br
Cl














OH
HO—P=O
N
O
OH
HO—P=O
N
O
CH3
CH3
O
Br
OH
HO—P=O
N
O
CH3
CH3
O
Br
OH
HO—P=O
N
O
CH3
CH3
O
Br
OH
HO—P=O
N
O
CH3




OH
HO—P=O
N
CH3
O
Cl


OH
HO—P=O
N
CH3
CH3
CH3
O
OH
HO—P=O
N
CH3
CH3
O
Cl
OH
HO—P=O
N
CH3
O
O
CH3
OH
HO—P=O
N
O
CH3


OH
HO—P=O
N
O
CH3
OH
HO—P=O
N
O
CH3
OH
HO—P=O
N
OH
HO—P=O
N















22. (currently amended) A method of treating ~~can~~ an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

23 to 33 (canceled).

34. (original) A method of suppressing the immune system in a mammalian patient in need of immunosuppression comprising administering to said patient an immunosuppressing effective amount of a compound of Claim 1.

35. (original) A pharmaceutical composition comprised of a compound in accordance with Claim 1 in combination with a pharmaceutically acceptable carrier.